Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | HTR1B | P28222 | 3/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.32 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.32 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.32 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Propane SCHEMBL28109760 | 0.95 | ALDH1A1 (0.37) | ALDH1A1HTR1BEPHX2TSHRL3MBTL1 | |
| SCHEMBL2754824 | 0.87 | ALDH1A1 (0.33) | ALDH1A1HTR1B | |
| SCHEMBL22702566 | 0.85 | ALDH1A1 (0.35) | ALDH1A1EPHX2TSHRL3MBTL1SMN1; SMN2 | |
| SCHEMBL15980865 | 0.85 | KDM4E (0.39) | ALDH1A1HTR1BEPHX2ADRB2ADRB1 | |
| SCHEMBL15980866 | 0.85 | KDM4E (0.39) | ALDH1A1HTR1BEPHX2ADRB2ADRB1 | |
| SCHEMBL25053660 | 0.85 | KDM4E (0.39) | ALDH1A1HTR1BEPHX2ADRB2ADRB1 | |
| SCHEMBL15980862 | 0.85 | KDM4E (0.39) | ALDH1A1HTR1BEPHX2ADRB2ADRB1 | |
| SCHEMBL21106553 | 0.85 | KDM4E (0.39) | ALDH1A1HTR1BEPHX2ADRB2ADRB1 | |
| SCHEMBL12703408 | 0.84 | ALDH1A1 (0.50) | ALDH1A1HTR1BTSHRL3MBTL1ADRB2 | |
| SCHEMBL24477365 | 0.82 | ALDH1A1 (0.44) | ALDH1A1HTR1BADRB2NR2E1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2640724-A1 | NOVEL INDOLIZINE DERIVATIVES, AND PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-09-25 | — | — | EP | claimed |
| US-20130245006-A1 | NOVEL INDOLIZINE DERIVATIVES, AND PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-09-19 | — | — | US | claimed |
| WO-2012066234-A9 | NOVEL INDOLIZINE DERIVATIVES, AND PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-11-01 | — | — | WO | claimed |
| WO-2012066234-A1 | NOVEL INDOLIZINE DERIVATIVES, AND PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-05-24 | — | — | WO | claimed |
| EP-3883926-B1 | BIS-OCTAHYDROPHENANTHRENE CARBOXAMIDE DERIVATIVES AND PROTEIN CONJUGATES THEREOF FOR USE AS LXR AGONISTS | REGENERON PHARMA (US) | 2024-07-10 | — | — | EP | disclosed |
| EP-4310496-A2 | COMPOUNDS FOR TAU PROTEIN DEGRADATION | Dana-Farber Cancer Institute, Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| US-20230285581-A1 | RIFAMYCIN ANALOGS AND ANTIBODY-DRUG CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2023-09-14 | — | — | US | disclosed |
| WO-2023172737-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. (US) | 2023-09-14 | — | — | WO | disclosed |
| US-11732008-B2 | Preparation of functional homocysteine residues in polypeptides and peptides | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-08-22 | — | — | US | disclosed |
| WO-2023144379-A1 | HIGH-AFFINITY LIGANDS OF FIBROBLAST ACTIVATION PROTEIN FOR TARGETED DELIVERY APPLICATIONS | PHILOCHEM AG (CH) | 2023-08-03 | — | — | WO | disclosed |
| US-20230219945-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| WO-2023129518-A1 | TUBULYSINS AND PROTEIN-TUBULYSIN CONJUGATES | REGENERON PHARMACEUTICALS, INC. (US) | 2023-07-06 | — | — | WO | disclosed |
| US-20100016319-A1 | ARYLMETHYLENE UREA DERIVATIVE AND USE THEREOF | TORAY INDUSTRIES, INC. A CORPORATION OF JAPAN (JP) | 2010-01-21 | — | — | US | disclosed |
| US-20090264405-A1 | Cetp Inhibitors | MERCK SHARP & DOHME LLC | 2009-10-22 | — | — | US | disclosed |
| US-20090264405-A1 | Cetp Inhibitors | MERCK SHARP & DOHME LLC | 2009-10-22 | — | — | US | disclosed |
| US-20090227621-A1 | Naphthyridine derivatives having inhibitory activity against hiv integrase | SHIONOGI & CO., LTD. (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090186870-A1 | Therapeutic Agents - 802 | ASTRAZENECA AB (SE) | 2009-07-23 | — | — | US | disclosed |
| US-20060058315-A1 | 2-Oxo-ethanesulfonamide derivates | ASTRAZENECA AB (SE) | 2006-03-16 | — | — | US | disclosed |
| EP-1562574-A1 | 2-OXO-ETHANESULFONAMIDE DERIVATES | Astrazeneca AB (SE) | 2005-08-17 | — | — | EP | disclosed |
| WO-2004041264-A1 | 2-OXO-ETHANESULFONAMIDE DERIVATES | ASTRAZENECA AB (SE) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264405-A1 | Cetp Inhibitors | CETP, APOB, PCSK9 | ALDH1A1 3312/4885HTR1B 3483/4885EPHX2 2155/4885 |
| US-20130245006-A1 | NOVEL INDOLIZINE DERIVATIVES, AND PREPARATION AND THERAPEUTIC USE THEREOF | INMT, TPH2, IDO2 | ALDH1A1 1356/4885HTR1B 14/4885EPHX2 3024/4885 |
| US-20100016319-A1 | ARYLMETHYLENE UREA DERIVATIVE AND USE THEREOF | UROD, UTS2R, SLC14A1 | ALDH1A1 250/4885HTR1B 2831/4885EPHX2 1918/4885 |
| US-20090186870-A1 | Therapeutic Agents - 802 | GPR119, SLC5A2, MC2R | ALDH1A1 918/4885HTR1B 3009/4885EPHX2 1891/4885 |
| US-20060058315-A1 | 2-Oxo-ethanesulfonamide derivates | HSD11B1, HSD3B1, HSD11B2 | ALDH1A1 65/4885HTR1B 626/4885EPHX2 405/4885 |
| US-20230219945-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | ALDH1A1 2776/4885HTR1B 3501/4885EPHX2 1890/4885 |
| US-11732008-B2 | Preparation of functional homocysteine residues in polypeptides and peptides | BHMT2, BHMT, PTMS | ALDH1A1 4389/4885HTR1B 840/4885EPHX2 2271/4885 |
| US-20090227621-A1 | Naphthyridine derivatives having inhibitory activity against hiv integrase | PNP, CDKL1, ASNS | ALDH1A1 2740/4885HTR1B 2935/4885EPHX2 3619/4885 |
| US-20230285581-A1 | RIFAMYCIN ANALOGS AND ANTIBODY-DRUG CONJUGATES THEREOF | ASGR1, CUTA, SRPRA | ALDH1A1 3411/4885HTR1B 4034/4885EPHX2 4135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.